Recombinant Human PGK1 Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-1595NP
BL-1595NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-1595NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human PGK1 Protein (C-6His)

Beta LifeScience SKU/CAT #: BL-1595NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human Phosphoglycerate Kinase 1 is produced by our Mammalian expression system and the target gene encoding Ser2-Ile417 is expressed with a 6His tag at the C-terminus.
Accession P00558
Synonym Phosphoglycerate kinase 1;Cell migration-inducing gene 10 protein;Primer recognition protein 2;PGK1;PGKA
Gene Background Phosphoglycerate kinase 1(PGK1) is an enzyme. It is mainly expressed in spermatogonia and Localized on the principle piece in the sperm. Its expression significantly decreased in the testis of elderly men. PGK1 involved in a critical energy-producing process known as glycolysis. It helps carry out a chemical reaction that converts a molecule called 1,3-diphosphoglycerate, which is produced during the breakdown of glucose, to another molecule called 3-phosphoglycerate during glycolysis. PGK1 may also act as a cofactor for polymerase alpha. The protein has been identified as a moonlighting protein based on its ability to perform mechanistically distinct functions.
Molecular Mass 45.5 KDa
Apmol Mass 37-50 KDa, reducing conditions
Formulation Supplied as a 0.2 μm filtered solution of 20mM Tris-HCl, 150mM NaCl, 20% Glycerol, pH 8.0.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution
Storage Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Catalyzes one of the two ATP producing reactions in the glycolytic pathway via the reversible conversion of 1,3-diphosphoglycerate to 3-phosphoglycerate. In addition to its role as a glycolytic enzyme, it seems that PGK-1 acts as a polymerase alpha cofactor protein (primer recognition protein). May play a role in sperm motility.
Subcellular Location Cytoplasm.
Protein Families Phosphoglycerate kinase family
Database References
Associated Diseases Phosphoglycerate kinase 1 deficiency (PGK1D)
Tissue Specificity Mainly expressed in spermatogonia. Localized on the principle piece in the sperm (at protein level). Expression significantly decreased in the testis of elderly men.

Gene Functions References

  1. PGK1 mutated variants display different catalytic activity and conformational stability compared to the native enzyme. PMID: 29995887
  2. The results indicate that ALDOA and PGK1 may indicate resistance to cisplatin in osteosarcoma PMID: 29199648
  3. PGK1 is used to indicate the prognosis of hepatocellular carcinoma (HCC). PMID: 28749413
  4. Data show that LINC00963 (MetaLnc9) interacted with the glycolytic kinase PGK1 and prevented its ubiquitination in non-small cell lung cancer (NSCLC) cells, leading to activation of the oncogenic AKT/mTOR signaling pathway. PMID: 28923857
  5. Acetylated PGK1 binds to and phosphorylates Beclin1 at S30, leading to activation of the VPS34-Beclin1 complex to initiate autophagosomal formation. PMID: 28238651
  6. Data suggest that, in breast cancer cells, MYC acts as an upstream regulator leading to PGK1 activation. (MYC, proto-oncogene c-myc; PGK1, phosphoglycerate kinase 1) PMID: 28457968
  7. PGK1, a glycolytic enzyme catalyzing the conversion of 3-phosphoglycerate into 2-phosphoglycerate, has increased expression in synovial tissues and blood of rheumatoid arthritis, which may be involved in pro-inflammation and synovial hyperplasia of the disease PMID: 27342824
  8. In neuroblastoma cells, CAIX and PGK1 expression is up regulated under hypoxia and correlates with response to targeted anti-proliferative treatment. PMID: 26510737
  9. Mitochindrial PGK1 acts as a protein kinase in coordinating glycolysis and the tricarboxylic acid cycle, which is instrumental in cancer metabolism and tumorigenesis. PMID: 26942675
  10. PI3K/AKT/mTOR pathway regulates HDAC3 S424 phosphorylation, which promotes HDAC3-PGK1 interaction and PGK1 K220 deacetylation PMID: 26356530
  11. Retinal dystrophy may be one of the clinical manifestations of phosphoglycerate kinase deficiency. PMID: 26396085
  12. mutations associated with hPGK1 deficiency lead to increased aggregation and proteolysis rates in vitro and inside cells due to protein thermodynamic destabilization PMID: 24838780
  13. Results show that PGK1 mRNA and protein expression were significantly increased in breast cancer tissues and can be considered as a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer. PMID: 25867275
  14. Suppression of PGK1 enhanced the radiosensitivity of U251 xenografts and suggest that PGK1 may serve as a useful target in the treatment of radioresistant glioma. PMID: 25175369
  15. Phosphoglycerate kinase deficiency due to a novel mutation (c. 1180A>G) manifesting as chronic hemolytic anemia in a Japanese boy. PMID: 24934115
  16. PGK1 appears to play an important role for neuroblastoma PMID: 24376734
  17. different factors contributing to hPGK1 thermodynamic and kinetic stability PMID: 24721582
  18. PGK1 could promote radioresistance in U251 human cells. PMID: 24284928
  19. increased expression of PGK1 in colon cancer tissue is associated with metastasis. PMID: 23727790
  20. Generif: Phosphoglycerate kinase is a moonlighting protein that functions as both a glycolytic enzyme and a primer recognition protein of DNA polymerase alpha. PMID: 2324090
  21. Phosphoglycerate kinase is a moonlighting protein that functions as both a glycolytic enzyme and a disulfide reductase. PMID: 11130727
  22. Conformational dynamics in the catalytic cycle of phosphoglycerate kinase, molecular details provided by structural analysis. [Review] PMID: 23684636
  23. Glycolytic enzymes PGK1 and PKM2 are novel transcriptional targets of PPARgamma in breast cancer. PMID: 23130662
  24. the low kinetic stability displayed by PGK1 protein mutations is causing human PGK1 deficiency PMID: 23336698
  25. Phosphoglycerate kinase 1 was up-regulated significantly in radioresistant astrocytomas and also seems to be correlated with the negative prognosis following radiotherapy. PMID: 22742733
  26. carbonic anhydrase I, phosphoglycerate kinase 1 and apolipoprotein A-I appeared to be the most significant variations of proteins in patients with osteopenia and osteoarthritis PMID: 22619369
  27. two key (hub) PPARgamma direct target genes, PRKCZ and PGK1, were experimentally validated to be repressed upon PPARgamma activation by its natural ligand, 15d-PGJ2 in three prostrate cancer cell lines PMID: 21780947
  28. All findings indicate that the different clinical manifestations associated with PGK1 deficiency chiefly depend on the distinctive type of perturbations caused by mutations in the PGK1 gene PMID: 22348148
  29. enzyme kinetics studies show that the absence of the ribose OH-groups with is better tolerated for the purine than for the pyrimidine containing compounds in phosphoglycerate kinase 1 PMID: 21505655
  30. Molecular dynamics simulations were carried out with four different nucleotides (D-/L-ADP and D-/L-CDP) in complex with PGK and 1,3-bisphospho-d-glycerate. The binding affinities of CDPs were very weak while D- and L-ADP were better substrates. PMID: 21549683
  31. PGK domain movement and catalysis is regulated by a spring-loaded release mechanism PMID: 21349853
  32. Phosphoglycerate kinase 1 (PGK1) showed a difference between follicular cells from follicles leading to a pregnancy or developmental failure. PMID: 19778949
  33. PGK1-overexpressing fibroblasts with prostate tumor cells promoted tumor cell growth in vivo. Observations suggest that PGK1 helps support the interactions between cancer and its microenvironment. PMID: 20068185
  34. Data show that PGK1 regulates the expression of CXCR4 and beta-catenin at the mRNA and protein levels. PMID: 19688824
  35. Results suggest that conformational rearrangements in the hinge generated by binding of both substrates provide the main driving force for domain closure overcoming the slightly unfavourable contact interactions between the domains. PMID: 19854185
  36. Phosphorylates pyrimidine L-deoxynucleoside analog diphosphaates PMID: 12080078
  37. Overexpression induces a multidrug resistance phenotype. PMID: 12174867
  38. 3-phosphoglycerate kinase has a role in the activation of L-nucleoside analogs PMID: 12869554
  39. These results demonstrate that phosphpglycerate kinase regulates uPAR expression at the post-transcriptional level. PMID: 14764427
  40. production and secretion of PGK are regulated separately and oxygen and the protein hydroxylases can control not only gene expression but also protein secretion PMID: 15053920
  41. phosphoglycerate kinase does not appear to have a role in the development or progression of neoplasms [letter] PMID: 15255553
  42. During domain closure, Lys 215 in 3-phosphoglycerate kinase possibly moves together with the transferring phosphate, and this group is being positioned properly for catalysis. PMID: 16363799
  43. The impact of hypoxic treatment on the expression of PGK1 and the cytotoxicity of troxacitabine and gemcitabine are reported. PMID: 17565005
  44. our study indicates that inhibition of the transcription mechanism is the cause of PGK deficiency. PMID: 17661373
  45. Aa steady state kinetic and biophysical study of the interaction of the model compound l-MgADP with hPGK, is presented. PMID: 18096512
  46. Although L-ADP is almost as catalytically competent as D-ADP, under our experimental conditions (buffer containing 30% methanol, 4 degrees C) phosphoglycerate kinase binds D- and L-ADP with similar kinetics. PMID: 18288812
  47. overexpression of PGK1 and its signalling targets may be a expression-pathway in diffuse primary gastric carcinomas promoting peritoneal dissemination PMID: 18453750
  48. transmission path of the nucleotide effect toward the main hinge of phosphoglycerate kinase is described for the first time at the level of interactions existing in the tertiary structure[ 3-phosphoglycerate kinase] PMID: 18540639
  49. PGK1 was selectively overexpressed in human colon tumor cells by treating with hydrogen peroxide as oxidative stress, while its expression was suppressed by co-treatment with antioxidants. PMID: 18603805

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

Recently viewed